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ORIGINAL ARTICLE
Tolerability of nausea and vomiting and associations with weight
loss in a randomized trial of liraglutide in obese, non-diabetic
adults
MEJ Lean1, R Carraro2, N Finer3, H Hartvig4, ML Lindegaard4, S Ro¨ssner5, L Van Gaal6 and A Astrup7 on behalf of the NN8022-1807
Investigators8
BACKGROUND: Liraglutide 3.0mg, with diet and exercise, produced substantial weight loss over 1 year that was sustained over 2
years in obese non-diabetic adults. Nausea was the most frequent side effect.
OBJECTIVE: To evaluate routinely collected data on nausea and vomiting among individuals on liraglutide and their inﬂuence on
tolerability and body weight.
DESIGN: A randomized, placebo-controlled, double-blind 20-week study with an 84-week extension (sponsor unblinded at 20
weeks, open-label after 1 year) in eight European countries (Clinicaltrials.gov: NCT00422058).
SUBJECTS: After commencing a 500-kcal/day deﬁcit diet plus exercise, 564 participants (18–65 years, body mass index (BMI)
30–40 kgm 2) were randomly assigned (after a 2-week run-in period) to once-daily subcutaneous liraglutide (1.2, 1.8, 2.4 or
3.0mg), placebo or open-label orlistat (120mg 3 per day). After 1 year, participants on liraglutide/placebo switched to liraglutide
2.4mg, and subsequently, to liraglutide 3.0mg (based on 20-week and 1-year results, respectively).
RESULTS: The intention-to-treat population comprised 561 participants (n¼ 90–98 per arm, age 45.9±10.3 years, BMI
34.8±2.7 kgm 2 (mean±s.d.)). In year 1, more participants reportedX1 episode of nausea/vomiting on treatment with liraglutide
1.2–3.0mg (17–38%) than with placebo or orlistat (both 4%, Pp0.001). Most episodes occurred during dose escalation (weeks 1–6),
with ‘mild’ or ‘moderate’ symptoms. Among participants on liraglutide 3.0mg, 48% reported some nausea and 13% some vomiting,
with considerable variation between countries, but only 4 out of 93 (4%) reported withdrawals. The mean 1-year weight loss on
treatment with liraglutide 3.0mg from randomization was 9.2 kg for participants reporting nausea/vomiting episodes, versus 6.3 kg
for those with none (a treatment difference of 2.9 kg (95% conﬁdence interval 0.5–5.3); P¼ 0.02). Both weight losses were
signiﬁcantly greater than the respective weight losses for participants on placebo (Po0.001) or orlistat (Po0.05). Quality-of-life
scores at 20 weeks improved similarly with or without nausea/vomiting on treatment with liraglutide 3.0mg.
CONCLUSION: Transient nausea and vomiting on treatment with liraglutide 3.0mg was associated with greater weight loss,
although symptoms appeared tolerable and did not attenuate quality-of-life improvements. Improved data collection methods on
nausea are warranted.
International Journal of Obesity (2014) 38, 689–697; doi:10.1038/ijo.2013.149
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INTRODUCTION
Obesity is described by the WHO (World Health Organization) as
one of the most important public health threats.1,2 It is a major
factor in the development of type 2 diabetes mellitus,
cardiovascular disease, hypertension, certain cancers, sleep
apnea, osteoarthritis and depression.3 Obese individuals often
have lower self-esteem and a poorer quality of life (QoL) than do
normal-weight individuals.4,5 Within routine primary care, diet and
exercise-based intervention can be cost-effective, but only a small
minority6 achieve the45% weight loss at 12 and 24 months that
is associated with improvements in obesity-related cardiovascular
and metabolic risk factors.7–11 A largely unmet medical need for
adjunctive and effective anti-obesity pharmacotherapy exists.12
The safety and side-effect proﬁles of pharmaceutical agents are in
particular focus because obesity is usually a chronic condition
demanding long-term treatment.13,14
Liraglutide is an analog of the incretin and satiety hormone,
glucagon-like peptide-1 (GLP-1), which decreases energy intake
and promotes weight loss and glucose-stimulated insulin
release.15–22 Subcutaneous liraglutide (Victoza, Novo Nordisk A/S,
Bagsvaerd, Denmark), at once-daily doses of up to 1.8mg per day,
is approved in the EU and US for the treatment of type 2 diabetes
mellitus,23,24 and liraglutide 3.0mg per day is currently under
investigation for weight management. A phase 2 randomized,
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placebo-controlled trial in 564 obese non-diabetic adults showed
that liraglutide was more effective than orlistat or diet and
exercise alone at reducing weight (the primary endpoint).25,26
From randomization, participants on liraglutide 3.0mg lost 7.2 kg
of mean body weight at 20 weeks and 7.8 kg at 1 year (analysis of
covariance). After 2 years, participants who had been randomized
to liraglutide 2.4 or 3.0mg (pooled group) sustained a mean
weight loss of 5.3 kg. Those completing the full 2-year treatment
period lost 7.8 kg from the time of commencing weight loss at
run-in. The most frequently reported side effect with liraglutide
was nausea, known to be induced by supraphysiological levels of
native GLP-1 and by GLP-1 receptor agonists.14,18,27,28 In phase 3
trials of liraglutide for type 2 diabetes mellitus, nausea was
reported by up to 40% of individuals on liraglutide 1.2 or 1.8mg
per day, but was mostly mild and transient.29 Similarly, in this trial
involving obese individuals, nausea was also the most frequently
reported side effect, occurring mostly early in the trial during dose
escalation.25 Vomiting, reported less frequently, also had a higher
incidence among individuals on liraglutide treatment.
The aim of the current paper was to document more closely the
data on nausea and vomiting from the phase 2 trial of liraglutide
at doses of up to 3.0mg per day in non-diabetic obese adults25,26
in terms of incidence and tolerability and the relationship to
weight loss.
PARTICIPANTS AND METHODS
Full details of the study design and participants recruited have been
published.25,26 Local ethics committees approved the trial protocol, and
the trial was performed according to the Declaration of Helsinki30 and
guidelines for Good Clinical Practice. The trial is registered with
Clinicaltrials.gov, number NCT00422058.
Participants
Obese men and women gave informed written consent to participate in
the trial, which was conducted at 19 clinical research centers in eight
countries across Europe from January 2007 to April 2009. Eligible
participants were aged 18–65 years and were of stable weight, with body
mass index (BMI) of 30–40 kgm 2 and fasting plasma glucose of
o7mmol l 1 (126mgdl 1) at the start of the run-in period. Individuals
were excluded if they had been diagnosed with type 1 or 2 diabetes
mellitus or major medical conditions, had used approved weight-loss
drugs within the previous 3 months, had received drug treatment known
to induce weight gain or had received surgical obesity treatment.
Study design
The study design is shown in Figure 1. Participants commenced weight
loss with a 2-week ‘run-in’ period (diet, exercise and placebo injections),
starting one week after screening. They were then randomized to
treatment for 20 weeks, and most consented to enroll in the extension,
continuing blinded on randomized treatment for a further 32 weeks
(52 weeks in total). At week 20, the sponsor was unblinded to liraglutide/
placebo treatment, whereas the participants and investigators remained
blinded up to 1 year. After 1 year, when the 20-week data had been
analyzed, the trial was fully unblinded. At 1 year, participants on liraglutide
and placebo treatment switched to open-label treatment with liraglutide
2.4mg, deemed the optimal dose from analysis of the 20-week data,
undergoing dose escalation as necessary. However, after analysis of the
1-year efﬁcacy and safety data, the 3.0-mg dose was, instead, considered
optimal. Participants on liraglutide 2.4mg therefore switched to liraglutide
3.0mg in weeks 70–96 (timing was variable, occurring as sites obtained
ethics-committee approval). Individuals on orlistat remained on a standard
3 120-mg dose for the full 2-year period. For the current paper, weight
changes from randomization are given. It is of note that there was an
additional mean weight loss of 1.3±1.4 kg during the run-in period prior
to randomization.25
Treatment
After the run-in period, individuals were randomly assigned to double-
blinded treatment (liraglutide, placebo or orlistat). Liraglutide doses of 1.2,
1.8, 2.4 or 3.0mg were administered once daily by evening subcutaneous
injection using a pre-ﬁlled injection pen (FlexPen, Novo Nordisk A/S,
Bagsvaerd, Denmark) with NovoFine Needles 8mm 30G (Novo Nordisk
A/S), starting with doses of 0.6mg per day and increasing by weekly
increments of 0.6mg (dose escalation). The open-label comparator group
was randomized to receive orlistat capsules (3 120mg per day) (Xenical,
Roche, Basel, Switzerland) with each main meal for the full 2-year period.
During the run-in period and throughout treatment, all participants
received dietary counseling for a nutritionally balanced low-calorie diet
(with about 30% of total caloric intake from fat, 20% from protein and 50%
from carbohydrates), providing an energy deﬁcit of approximately 500 kcal
per day below the estimated 24-h energy requirements31 (calculated as
basal metabolic rate physical activity level 1.3). Participants were also
advised to maintain or increase physical activity.
Study measures
For regulatory purposes, side effects were recorded as adverse events and
as responses to open questions at every visit or telephone contact from
screening and up to 1 week after the last day on treatment. All adverse
events (serious and non-serious) were coded using the Medical Dictionary
for Regulatory Activities version 10.1. Information about nausea or
vomiting was thus collected as part of a routine adverse event collection.
Liraglutide 2.4 mg
Liraglutide 3.0 mg s.c.
Randomization
n=564
Screening
Wk -3
Placebo
run-in: Wk -2
20 weeks
472 completed
year 2
268 completed
year 1
356 completed
Placebo s.c.
Orlistat 120 mg x3
Liraglutide 1.8 mg s.c.
Liraglutide 2.4 mg s.c.
Liraglutide 1.2 mg s.c.
Lifestyle intervention: -500 kcal/day deficit diet + increased physical activity
Extension*
n=398
Double blind
BMI ≥30 and ≤40 kgm-2
Stable body weight
FPG <7.0 mmolL-1 at Wk -2
Inclusion criteria :
Age 18–65 years Liraglutide 3.0 mg
Switch was made
when approved locally
(between 70–96 weeks)
Figure 1. Study design. *During 20–52 weeks, participants/investigators remained blinded to liraglutide/placebo treatment, but the sponsor
was unblinded; after 1 year, all were unblinded.
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Participants had been made aware in the baseline subject information/
informed consent material of the main side effects of liraglutide (‘diarrhea,
nausea and in rare cases vomiting, and also headache and dizziness’). All
events observed by the investigator or reported by participants either
spontaneously or in response to open questions were recorded by the
investigator on an adverse event form; these data were used as the basis
for measuring the incidence of nausea and vomiting. The following
information was recorded on the form: adverse-event diagnosis (if known,
otherwise symptoms were listed), whether the event was serious or of
special interest (requiring completion of a separate form), the date of
onset, severity (mild, moderate or severe), outcome (recovered, recovering,
recovered with sequelae, not recovered, fatal or unknown), causality in
relation to the trial product (in the investigator’s opinion) and whether any
action regarding trial products was taken. A ‘mild’ event was characterized
by ‘no or transient symptoms, no interference with the subject’s daily
activities’; a ‘moderate’ event was characterized by ‘marked symptoms,
moderate interference with the subject’s daily activities’; and a ‘severe’ event
was characterized by ‘considerable interference with the subject’s daily
activities, unacceptable’.
According to the protocol, trial drug dose reduction or increase was not
allowed, and participants were to be withdrawn if they could not tolerate
treatment. However, intermittent pauses and slower dose escalation were
permitted on a case-by-case basis, after discussion with the sponsor.
A ‘serious’ adverse event was one that resulted in at least one of the
following outcomes: death, life-threatening experience, in-patient hospi-
talization or prolongation of existing hospitalization, persistent or
signiﬁcant disability, a congenital anomaly/birth defect or any event that,
based on appropriate medical judgment, jeopardizes the individual and
may require medical or surgical intervention to prevent one of the
described outcomes.
Health-related QoL was assessed using the Impact of Weight on Quality
of Life—Lite (IWQoL-Lite) questionnaire.32 IWQoL-Lite is a validated,
31-item, self-reported measure of weight-related QoL that assesses
physical function, self-esteem, sexual life, public distress and work.
Finally, body weight was measured at every visit, starting from the
screening visit, using calibrated scales.
Statistical analysis
The sample size estimation for the 20-week trial has been reported
previously.25,26 The effect of at least one episode of nausea/vomiting on
weight change was investigated by analysis of covariance, and the effect of
gender on the reporting of episodes of nausea/vomiting, as well as the
incidence of these, was tested using logistic regression. These were post-hoc
analyses performed on a modiﬁed intention-to-treat population
(comprising randomized individuals having at least one treatment dose
and at least one post-randomization assessment) using last-observation-
carried-forward. Analyses at year 1 tested the superiority of each liraglutide
dose over placebo and orlistat. At year 2, the superiority of liraglutide
(pooled group of participants on 2.4/3.0mg over 2 years) over orlistat was
assessed. IWQoL-Lite scores were transformed using scoring methods
provided in the IWQoL-Lite scoring manual, with a score range of 0–100.
Differences in QoL of individuals experiencing some nausea/vomiting
versus those who did not were assessed using analysis of covariance post-
hoc. For analysis of covariance, treatment, country and sex were ﬁxed
effects, and randomization value was a covariate, with multiplicity
adjustment being made using Dunnett’s method. The same model
parameters were used for the regression analyses, using Bonferroni
correction for multiplicity adjustment. All analyses were two-sided, with 5%
signiﬁcance, and were performed using the Statistical Analysis System
software package (version 9.1; SAS Institute, Cary, NC, USA).
RESULTS
Trial population
Of 616 individuals entering the 2-week run-in period, 52 (8%)
withdrew, leaving 564 to receive randomized treatment: 135 men
(24%) and 429 women (76%). 472 completed the 20-week trial and
398 chose to enroll in the extension period (74 discontinued),
with 268 completing the full 2-year period (Figure 1 and
Supplementary Figure 1). Of the 93 participants randomized to
liraglutide 3.0mg, 82 (88%) completed 20 weeks and 65 remained
on liraglutide 3.0mg at 1 year (30% withdrawals, including 10 who
elected not to enroll in the extension at 20 weeks). At 2 years, 47
of the participants randomized to liraglutide 3.0mg were still
taking this dose (2-year withdrawal rate¼ 49%).
Three individuals randomized to liraglutide were excluded
from the intention-to-treat population owing to missing post-
randomization weight data. Major protocol deviations during the
trial have been described previously.25,26
Participant characteristics were comparable across groups at
randomization (Table 1) and on entering the extension (not
shown). The mean age was 45.9±10.3 (s.d.) years, and BMI was
34.8±2.7 kgm 2.
Incidence of nausea and vomiting during year 1
The frequency of nausea and/or vomiting for women (n¼ 135;
19% (95% conﬁdence interval (CI) 13–26%)) was not statistically
signiﬁcantly different from that of men (n¼ 29; 12% (95% CI
7–20%)): the odds ratio (female: male) was 1.7 (95% CI: 0.9–3.1;
P¼ 0.09). The proportion of individuals reporting nausea/vomiting
at any time during year 1 on liraglutide was dose-dependent
(Figure 2a), and statistically signiﬁcantly greater than with placebo
and orlistat for all liraglutide doses.
Reporting of nausea and vomiting by country
Reported incidence of nausea and vomiting varied widely
between the eight recruiting countries (Figures 2b and c). The
proportion of individuals on liraglutide (all doses) who reported
nausea ranged from 0/47 (0%) (Czech Republic) to 27/75 (36%)
(UK), and the proportion on liraglutide who reported vomiting
ranged from 0/11 (0%) (Belgium) to 13/75 (17%) (UK).
Timing
Most episodes of nausea (42/68 (62%)) among individuals on
liraglutide 3.0mg were ﬁrst reported in weeks 1–4, during dose
escalation (Table 2). A total of 7 out of 16 (44%) vomiting bouts
were reported in weeks 1–4, and 11 out of 16 (67%) were reported
in weeks 1–6 among individuals on liraglutide 3.0mg. No
Table 1. Participant characteristics at randomization (after 2-week diet, exercise, and placebo run-in period with mean weight loss of 1.3±1.4 kg)
Liraglutide
Placebo (n¼ 98) 1.2mg (n¼ 95) 1.8mg (n¼ 90) 2.4mg (n¼ 93) 3.0mg (n¼ 93) Orlistat (n¼ 95)
Male:female (%)a 25:75 23:77 24:76 24:76 25:75 23:77
Age (years)a 45.9 (10.3) 47.2 (9.7) 45.5 (10.9) 45.0 (11.1) 45.9 (10.7) 45.9 (9.1)
Weight (kg) 97.3 (12.3) 96.2 (13.5) 98.0 (12.5) 98.4 (13.0) 97.6 (13.7) 96.0 (11.7)
Body-mass index (kgm 2) 34.9 (2.8) 34.8 (2.6) 35.0 (2.6) 35.0 (2.8) 34.8 (2.8) 34.1 (2.6)
Waist (cm) 108 (10.0) 109 (10.4) 108 (9.5) 110 (10.7) 109 (8.3) 108 (9.7)
Total quality of life score 72 (19) 70 (17) 74 (15) 71 (20) 72 (20) 68 (20)
aNoted at screening. Values are mean (s.d.) unless otherwise stated. IWQoL-Lite quality of life scores ranged from 0 (worst) to 100 (best).
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participant in any group reported X4 nausea episodes. Episodes
of nausea reported by individuals on liraglutide 3.0mg after week
8 were mainly reported by those who had already experienced
earlier episodes (15/18 (83%)). Most nausea and vomiting
episodes were transient (data not shown). Data collected for
regulatory purposes did not allow an exact assessment of the
duration of reported symptoms or the frequencies of transient
symptoms occurring between visits and assessments.
Withdrawals and temporary dose reduction
Most liraglutide 3.0mg recipients who experienced nausea (36/45
participants (80%)) or vomiting (9/12 (75%)) reported only
one episode, and only 4 out of 93 (4%) withdrew because of
nausea/vomiting (one withdrew because of nausea; one withdrew
because of vomiting; one withdrew because of nausea and
vomiting; and one withdrew because of vomiting and diarrhea). In
addition to withdrawals owing to nausea and vomiting (Table 2),
one participant on liraglutide 1.8mg and 2 on 2.4mg withdrew for
‘other’ reasons (speciﬁcally, intolerance to the allocated dose) after
102, 64 and 65 days, respectively. No nausea episodes in the ﬁrst
year were rated ‘serious’ or led to temporary dose reduction or
drug withdrawal.
Severity
Most reported episodes of nausea and vomiting were of ‘mild’ or
‘moderate’ intensity (Figure 2d). Among individuals on liraglutide,
1.2 mg 1.8 mg 2.4 mg 3.0 mg
Liraglutide
OR 14.9 (6.2–35.5) vs. placebo
OR 13.4 (5.6–32.2) vs. orlistat
Both P<0.0001
OR 11.2 (4.7–26.9) vs. placebo
OR 10.2 (4.2–24.4) vs. orlistat
Both P<0.0001
OR 7.3 (3.1–17.6) vs. placebo
OR 6.6 (2.8–16.0) vs. orlistat
Both P<0.0001
OR 5.0 (2.0–12.1) vs. placebo
OR 4.5 (1.9–11.0) vs. orlistat
Both P<0.001
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73% of reported episodes of nausea were ‘mild’, 25% were
‘moderate’, and only 2% were ‘severe’. For vomiting, 46% of
episodes were ‘mild’, 46% ‘moderate’, and 9% ‘severe’. Sixteen
episodes of nausea among individuals on liraglutide were noted
as ‘intermittent nausea’ by the participant/investigator, compared
with two in the placebo group and one in the orlistat group; and
six cases of ‘intermittent vomiting’ were reported among
individuals on liraglutide.
Two episodes of vomiting were rated as ‘serious’ (Table 2). One
serious episode started after 135 days on liraglutide 2.4mg, and
recovery was registered after 2 days, occurring at the same time as
events of epigastric abdominal pain, nausea, headache and loss of
vision in the left eye. This woman recovered from the events with
no dose reduction, but withdrew consent to continue in the trial in
year 2. She had other gastrointestinal disturbances during the trial
(including diarrhea, retching and constipation as well as the
above). The other serious vomiting episode had its onset after 266
days of treatment with liraglutide 3.0mg, occurring simulta-
neously with an event of abdominal pain. Liraglutide was
temporarily withdrawn; the woman recovered after 8 days and
eventually completed the trial. She also had other gastrointestinal
disorders (including nausea and constipation) as well as chole-
lithiasis (gallstones). Weight loss data for the two individuals who
experienced the above events were not available.
Three non-serious vomiting episodes led to temporary dose
reduction or drug withdrawal. Liraglutide dose was reduced after
22 days (during escalation to 2.4mg) for one individual, who
subsequently withdrew because of nausea on day 33. Another
individual in the liraglutide 2.4mg group had a temporary dose
reduction after 2 days on account of vomiting, but recovered after
1 day and completed the trial. One in the orlistat group had
treatment temporarily withdrawn because of vomiting after 123
days (but recovered after 3 days and completed the trial).
Incidence of nausea and vomiting during year 2
The proportion of individuals experiencing nausea at any time
during 2 years of treatment is shown in Figure 2e. Just as
the incidence of nausea was highest during dose escalation at the
start of the trial, nausea was again observed at the start of the
second year in individuals in the placebo and liraglutide 1.2 and
1.8mg groups, when they switched to liraglutide 2.4mg. During
the 4-week dose-escalation period starting year 2, 23 individuals
(34%) who were previously on placebo experienced some nausea,
which was similar to the proportion undergoing dose escalation to
2.4mg in the ﬁrst year (32%). Only 3 of those 23 participants had
experienced nausea in year 1 while on placebo. Fewer individuals
who were already on liraglutide 1.2 and 1.8mg reported nausea
during dose escalation to 2.4mg: 16 and 6.8%, respectively. Only
one individual in each group already treated with liraglutide 2.4
and 3.0mg experienced nausea in the ﬁrst 4 weeks of year 2. No
participant experienced vomiting in the group randomized to
placebo during dose escalation to 2.4mg, whereas 11 (12%)
randomized to 2.4mg had reported vomiting in the ﬁrst 4 weeks
of the trial.
Association between nausea/vomiting and weight loss
After 1 year of treatment, the estimated mean weight loss from
randomization with liraglutide 3.0mg was 9.2 kg for those who
experienced at least one episode of nausea/vomiting (n¼ 49) and
6.3 kg for those who did not (n¼ 43) (a treatment difference of
2.9 kg (95% CI 0.5–5.3); P¼ 0.02) (Figure 3a). With liraglutide
3.0mg, weight loss in individuals who reported no nausea/
vomiting was still signiﬁcantly greater than in those on both
placebo (a treatment difference of 4.2 kg (2.1–6.4); P¼ 0.0001) and
orlistat (a treatment difference of 2.3 kg (0.14–4.4); P¼ 0.04). The
mean 1-year weight loss in individuals on liraglutide 3.0mg who
did experience episodes of nausea/vomiting was 7.8 kg (3.4–12.2)
greater than in those on placebo (P¼ 0.0006) and 6.6 kg (2.1–11.0)
greater than in those on orlistat (P¼ 0.004).
The estimated mean weight loss from randomization to year 2
for participants on liraglutide 2.4/3.0mg (pooled group) was also
signiﬁcantly greater for those who experienced at least one
episode of nausea/vomiting (6.9 kg, n¼ 93) compared with those
who did not (4.1 kg, n¼ 91) (a treatment difference of 2.9 kg
(0.8–4.9); P¼ 0.006) (Figure 3b).
Association between nausea/vomiting and QoL
QoL scores at 20 weeks improved from randomization among
individuals on liraglutide 3.0mg, and mean scores for physical
function, self-esteem and work were signiﬁcantly greater than for
those on placebo, as previously reported.25 No statistically
signiﬁcant differences were observed between individuals on
liraglutide 3.0mg who reported at least one episode of nausea/
vomiting over 20 weeks and those who did not (Figure 4).
DISCUSSION
We investigated the effects of liraglutide (at doses of up to 3.0mg
per day) on the incidence and tolerability of nausea and vomiting,
as well as on weight loss, in obese non-diabetic individuals.
Although these events were reported more often with liraglutide
than with either placebo or orlistat, symptoms were mostly mild or
moderate, transient and remarkably well tolerated. Nausea and
vomiting were associated with up to 2.9 kg more weight loss after
1 year of treatment, which suggests an association with at least
part of the mechanism of action of liraglutide-induced weight loss.
However, QoL assessed at 20 weeks was not impaired, even at the
highest 3.0-mg dose, which induced nausea in almost 50% of
individuals, mainly in weeks 1–4 during dose escalation. The
incidence of vomiting was lower, about a quarter of that of
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Figure 3. Weight change at year 1 (a) and year 2 (b) in individuals
with or without at least one episode of nausea or vomiting. Mean
changes (analysis of covariance) are shown for the intention-to-treat
population with the last observation carried forward. Estimated
treatment differences (ETD) are shown, together with 95% CI.
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nausea, for individuals on liraglutide 3.0mg, again mainly in the
ﬁrst 6 weeks. The incidence of nausea and vomiting was
comparable for males and females. No nausea episodes were
reported and only two vomiting episodes (reported in year 1,
together with symptoms suggesting recurrent illness rather than a
drug effect), were considered serious. Withdrawal from the study
on account of nausea or vomiting was uncommon.
These data originate from a clinical trial whose primary aim was
to investigate weight changes. Although information about
nausea and vomiting was not collected using a speciﬁc
questionnaire, it was possible to gain a reasonably clear under-
standing about such events from the data routinely reported on
adverse events. The nature of this process, as well as possible
differences in the way investigators inquired about and reported
adverse events in the different centers and countries, may have
affected the recording of these events. For instance, the incidence
of reported nausea and vomiting in the eight recruiting countries
varied substantially. The lack of systematic data collection on
nausea and vomiting, and duration of episodes, is a limitation of
this study, but is also an important lesson for future clinical trials.
Variability in the assessment of adverse events in clinical trials has
been previously reported.33,34 Considerable differences in the
categorization of adverse events were observed in an exercise
following training of investigators on data collection.34 In another
study of geographical variation in adverse-event reporting in 127
clinical trials of gastrointestinal indications, there were differences
in the reporting rates of general and serious adverse events across
the 13 countries involved.33 Notably in the current trial, nobody
from the Czech Republic reported nausea, nor did anyone from
Belgium report vomiting. Perhaps trial participants and
investigators tend to emphasize different kinds of adverse
events in different countries.33 It is also possible that the term
into which ‘nausea’ is translated has a subtly different meaning in
other languages, or can carry different cultural values, which may
inﬂuence spontaneous reporting. In English, for example, the
adjectives ‘nauseous’ or ‘nauseating’ may be used to indicate
something unpleasant or boring, and the word ‘nausea’ itself is
seldom used by non-health professionals.
In order to evaluate nausea and vomiting events more
accurately, use of a rating scale similar to the Gastrointestinal
System Rating Scale could be considered in future studies of drugs
such as liraglutide. In the current trial, in common with most
pharmaceutical trials, episodes of nausea and vomiting were only
reported in terms of the onset date and then the date of
‘outcome’ (if recorded, usually the date of the next trial visit).
Duration of single events, short episodes or ‘intermittent nausea’
could not be accounted for. Before enrollment, trial participants
were informed about diarrhea, nausea and (rarely) vomiting as
potential side effects associated with liraglutide. This could have
led to over-reporting of these symptoms. Standardized, reliable
ways to collect information on transient or intermittent adverse
events, including precise duration periods, are needed.
Liraglutide appears to modulate its effects on body weight in
the same way as native GLP-1,14,15,17,35,36 that is, through
concomitant inhibition of appetite and energy intake37,38 via
activation of both peripheral and central GLP-1 receptors,
although the exact mechanism is not known. The contribution
of nausea to reductions in appetite and energy intake is less clear.
In a study investigating the effect of gut hormones and appetite
perceptions on energy intake in men, nausea was identiﬁed as an
independent predictor of energy intake, although its effect size, as
a contribution to energy-intake suppression, was small.39 Nausea
occurs at the time of peak plasma liraglutide concentrations,40,41
and weekly dose escalation can help to mitigate its incidence and
severity.42 Nausea could be an effect of liraglutide on brain-stem
areas involved in the regulation of appetite and ﬂuid homeostasis
that are unprotected by the blood–brain barrier, as it has also
been reported by fasting individuals given GLP-1 or its
derivatives.40,43 Delayed gastric emptying has been associated
with nausea, and both could contribute to weight loss with GLP-1
receptor agonists. However, inhibition of gastric emptying
diminished within 14 days with liraglutide but not with
exenatide treatment, whereas similar weight loss occurred in
both groups.44 A recent study with liraglutide in rats suggests that
delayed gastric emptying is transient, and the main mechanism
for liraglutide-induced weight loss is mediated by stimulation of
appetite neurons in the brain.45
Weight loss in the current trial was signiﬁcantly greater for
individuals on liraglutide 3.0mg than for those on placebo (or
orlistat) after 1 year, and those on liraglutide 3.0mg who did not
report any nausea or vomiting also lost signiﬁcantly more weight
than those on placebo or orlistat. Thus, reported nausea
contributes to weight loss but is not the main mechanism behind
liraglutide-induced weight loss. Additional factors associated with
obesity that may compound the action of liraglutide to contribute
to a higher incidence of nausea and vomiting are a larger residual
gastric volume, increased esophageal reﬂux and increased
gallbladder and gastrointestinal disease.46
In the current study, reported nausea was intriguingly tolerable
for most affected individuals. Nausea and vomiting led to few
withdrawals in the ﬁrst year of treatment, and only two cases
(both vomiting) were rated as ‘serious’, both with features to
suggest intercurrent illness. Certain individuals may be more
susceptible to nausea, but our analysis did not speciﬁcally
examine predictors. Importantly, however, QoL was not impaired
in those who reported nausea/vomiting, improving to the same
extent at 20 weeks as for those who did not.
In summary, liraglutide is associated with dose-dependent
nausea, and almost half the individuals on liraglutide 3.0mg
reported nausea at some time over 1 year. Nausea occurs mostly
in the ﬁrst 4 weeks, during dose escalation, and is generally of
mild intensity. Nausea and vomiting are generally tolerable and
accepted as side effects of treatment. Considerable variation in the
reporting rates of nausea and vomiting in individual countries was
apparent in this trial, suggesting differences in reporting. Methods
of improving the consistency in adverse-event reporting are
warranted. Speciﬁcally, more accurate ways of collecting transient
or intermittent adverse events and precise duration periods
should be incorporated in future trials, with greater attention to
linguistic and cultural differences.
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